Vertex, Alios BioPharma collaborate to develop nucleotide drug candidates
ALS-2200 and ALS-2158, currently in preclinical development, are designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. As part of the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.